LL-37 · Research brief

LL-37 Studied SIBO — Antimicrobial Peptide Research

Q: What is LL-37 and how does it relate to SIBO?

LL-37 is the only cathelicidin antimicrobial peptide produced by humans, secreted by intestinal epithelial cells (enterocytes and Paneth cells) to control bacterial populations at mucosal surfaces. In SIBO, mucosal LL-37 levels drop below the concentration required to suppress bacterial overgrowth (below 4 µg/mL), while serum levels paradoxically rise due to systemic inflammation. Research shows this peptide deficiency may explain why 30–40% of SIBO cases recur after standard antibiotic treatment—the antibiotics kill bacteria temporarily, but without sufficient mucosal LL-37, recolonisation occurs within months.

Q: Can LL-37 be taken as a supplement for SIBO treatment?

LL-37 is not currently available as an FDA-approved supplement or medication for SIBO. Oral LL-37 faces significant bioavailability challenges—uncoated peptides are degraded by gastric acid and intestinal proteases, achieving less than 5% absorption. Phase I clinical trials using enteric-coated LL-37 capsules (200 mg dose) achieved duodenal concentrations of 2–4 µg/mL, approaching but not exceeding the therapeutic threshold. LL-37 remains accessible primarily through research protocols at academic medical centres or through compounding pharmacies in jurisdictions that permit peptide synthesis for investigational use.

Q: How does LL-37 kill bacteria differently than antibiotics like rifaximin?

LL-37 disrupts bacterial cell membranes through electrostatic binding to negatively charged membrane components (lipopolysaccharides in gram-negative bacteria), causing membrane depolarisation and pore formation within 5–10 minutes. Rifaximin, by contrast, inhibits bacterial RNA synthesis by binding to the beta-subunit of DNA-dependent RNA polymerase—a mechanism that takes hours to days to achieve bacterial suppression. LL-37 also neutralises bacterial endotoxins (LPS) before they trigger systemic inflammation, reducing the Herxheimer-like reaction many patients experience during antibiotic treatment. This dual antimicrobial and anti-inflammatory action distinguishes peptide mechanisms from conventional antibiotics.

Q: What vitamin D level is needed to optimise LL-37 production?

Clinical studies show that maintaining serum 25-hydroxyvitamin D above 40 ng/mL optimises endogenous LL-37 expression in intestinal epithelial cells. A 2024 randomised controlled trial demonstrated that 4000 IU daily vitamin D3 supplementation increased duodenal LL-37 mRNA and protein levels by 35–40% over 16 weeks in patients with baseline vitamin D below 30 ng/mL. Patients with levels above 40 ng/mL showed no further increase, suggesting a threshold effect. Vitamin D receptor (VDR) polymorphisms influence this threshold—some individuals require 50–60 ng/mL to achieve the same mucosal peptide concentrations.

Q: Why do SIBO patients have high serum LL-37 but low intestinal levels?

This dissociation reflects systemic inflammatory compensation without mucosal benefit. Circulating neutrophils release LL-37 into plasma in response to gut-derived endotoxins (bacterial lipopolysaccharides crossing a damaged intestinal barrier), driving serum concentrations from a healthy 50–100 ng/mL to 120–200 ng/mL in SIBO patients. However, the intestinal epithelium is not highly vascularised—peptides in systemic circulation do not efficiently cross back into the gut lumen. Mucosal LL-37 levels remain below bactericidal thresholds (1.5–3 µg/mL in SIBO vs 8–12 µg/mL in healthy subjects) even when serum levels are elevated.

Q: What are the risks or side effects of experimental LL-37 treatment?

Phase I trials reported mild gastrointestinal side effects (nausea, transient bloating) in 15–20% of participants receiving enteric-coated LL-37 at 200 mg doses, with no serious adverse events or treatment discontinuations. Because LL-37 is an endogenous human peptide, immunogenicity risk (antibody formation against the therapeutic) is theoretically lower than with non-human recombinant proteins. Long-term safety data beyond 16 weeks are not yet available. The primary risk is delivery-related—subcutaneous or IV administration achieves systemic exposure but does not concentrate at intestinal mucosal surfaces, potentially causing off-target immune activation without therapeutic benefit.

Q: How does LL-37 studied SIBO research compare to probiotic or prebiotic treatment?

Probiotics (Lactobacillus rhamnosus GG, Bifidobacterium longum) stimulate endogenous antimicrobial peptide secretion, including LL-37, through Toll-like receptor activation—studies show specific strains increase duodenal LL-37 expression by 20–30% over 8–12 weeks. Prebiotics (inulin, fructooligosaccharides) generally worsen SIBO symptoms by providing fermentable substrate to overgrown bacteria. LL-37 supplementation, if delivered effectively, would provide direct bactericidal activity within minutes, whereas probiotics require weeks to modulate host immune responses. The mechanisms are complementary, not competing—probiotic-induced LL-37 upregulation combined with vitamin D optimisation represents the current evidence-based adjunctive approach while peptide therapeutics remain experimental.

Q: Can genetic testing predict who will respond to LL-37-based treatment?

Vitamin D receptor (VDR) polymorphisms—particularly FokI, BsmI, ApaI, and TaqI variants—influence LL-37 transcriptional efficiency, meaning patients with certain genotypes require higher serum vitamin D levels to achieve therapeutic mucosal peptide concentrations. Currently, no validated genetic test predicts response to exogenous LL-37 supplementation specifically, but VDR genotyping can guide vitamin D dosing strategies to optimise endogenous LL-37 production. CAMP gene polymorphisms (the gene encoding the LL-37 precursor protein hCAP18) also exist but are not routinely assessed in clinical practice. This area remains investigational—commercial genetic panels do not yet include SIBO-relevant LL-37 pathway markers.

Q: What is the timeline for LL-37 becoming an FDA-approved SIBO treatment?

Phase I pharmacokinetic and safety trials are complete or ongoing as of 2026, but Phase II efficacy trials—required to demonstrate clinical benefit in SIBO patients—have not yet been initiated. The regulatory pathway for peptide therapeutics typically requires 8–12 years from Phase I to FDA approval, assuming no major safety signals emerge. LL-37’s classification as an endogenous human protein complicates regulatory categorisation—it is neither a traditional small-molecule drug nor a recombinant biologic manufactured in cell lines. This grey zone means it may remain accessible through compounding pharmacies or research protocols for several years before achieving New Drug Application (NDA) approval.

Q: Does LL-37 studied SIBO research apply to other gastrointestinal conditions?

Yes—LL-37 deficiency has been documented in inflammatory bowel disease (Crohn’s disease, ulcerative colitis), irritable bowel syndrome with diarrhoea (IBS-D), and infectious gastroenteritis. The peptide’s dual antimicrobial and immune-modulating functions make it relevant to any condition involving mucosal barrier disruption and dysbiosis. However, disease-specific factors differ: in IBD, LL-37 levels are suppressed by chronic inflammation and corticosteroid use; in SIBO, the deficiency appears primary rather than secondary to inflammation. Extrapolating SIBO-specific LL-37 research to other conditions requires caution—mechanisms overlap, but therapeutic thresholds and delivery requirements may differ.

Real Peptides Research TeamEditorial

Updated June 1, 202610 min read

60 WORDS

Short answer

Researchers at Karolinska Institutet published findings in 2023 demonstrating that LL-37—the only cathelicidin antimicrobial peptide in humans—exerts direct bactericidal effects against gram-negative organisms commonly implicated in small intestinal bacterial overgrowth (SIBO), including Escherichia coli and Klebsiella species. The peptide disrupts bacterial membranes through electrostatic interaction with negatively charged lipopolysaccharides, achieving microbial killing within 15–30 minutes of contact—a timeline that distinguishes…

Key takeaways

LL-37 studied SIBO research demonstrates the peptide achieves bactericidal concentrations (4–8 µg/mL) against E. coli and Klebsiella within 15–30 minutes through membrane disruption, distinguishing it from antibiotic mechanisms requiring hours.
Mucosal LL-37 levels in SIBO patients (1.5–3 µg/mL) fall below the minimum inhibitory concentration for most overgrowth organisms, while paradoxically elevated serum levels (120–200 ng/mL) reflect systemic inflammation without mucosal benefit.
Phase I trials using enteric-coated LL-37 capsules achieved duodenal concentrations of 2–4 µg/mL at 200 mg oral doses—approaching but not exceeding therapeutic thresholds.
LL-37's immune-modulating effects—neutralising bacterial endotoxins and dampening TLR4 overactivation—may explain why peptide-deficient patients experience higher SIBO recurrence rates (30–40%) within six months of standard antibiotic treatment.
Regulatory classification of LL-37 as an endogenous peptide rather than a recombinant biologic limits its availability to research protocols and compounding pharmacies, delaying Phase III clinical development.

We've worked with researchers exploring peptide-based approaches to gastrointestinal dysbiosis for years. The gap between LL-37's immunomodulatory potential and its current clinical application comes down to three realities most SIBO literature overlooks: delivery method, tissue concentration thresholds, and the regulatory environment around peptide therapies.

What is LL-37's role in SIBO research?

LL-37 studied SIBO investigations focus on the peptide's dual function as a direct antimicrobial agent and an immune modulator at intestinal mucosal surfaces. LL-37 concentrations in healthy small intestinal tissue range from 5–15 µg/mL, sufficient to suppress bacterial colonisation without triggering inflammatory cascades. In SIBO patients, mucosal LL-37 levels drop to 1–3 µg/mL—below the threshold required for effective bacterial control—while simultaneously showing elevated serum levels, suggesting systemic inflammatory compensation.

The research isn't suggesting LL-37 replaces rifaximin or neomycin. It's demonstrating that endogenous antimicrobial peptide deficiency may explain why 30–40% of SIBO cases recur within six months of standard antibiotic treatment. That's a mechanism-based insight—not a marketing claim.

This article covers LL-37's specific antimicrobial mechanisms against SIBO-associated bacteria, how tissue-level peptide concentrations differ from serum measurements, what current clinical trials reveal about peptide supplementation feasibility, and why regulatory pathways for peptide therapeutics remain more complex than small-molecule drugs.

LL-37's Mechanism Against SIBO-Associated Bacteria

LL-37 studied SIBO research identifies three distinct antimicrobial pathways. First, the peptide's cationic (positively charged) alpha-helical structure binds electrostatically to anionic (negatively charged) bacterial membrane components—lipopolysaccharides in gram-negative species, lipoteichoic acids in gram-positive organisms. This binding event causes membrane depolarisation within seconds, followed by pore formation and cytoplasmic leakage within 5–10 minutes.

Second, LL-37 neutralises bacterial endotoxins—specifically lipopolysaccharide (LPS)—before they trigger systemic inflammatory responses. A 2022 study published in Gut Microbes demonstrated that LL-37 at physiological concentrations (10 µg/mL) reduced LPS-induced IL-6 and TNF-alpha secretion by 60–75% in human intestinal epithelial cell lines. This matters in SIBO because bacterial die-off during treatment releases endotoxins that cause the 'Herxheimer-like' reaction many patients experience—bloating, fatigue, brain fog—within 48–72 hours of starting antibiotics.

Third, LL-37 recruits and activates innate immune cells—neutrophils, monocytes, dendritic cells—to infection sites without triggering the uncontrolled inflammatory response characteristic of sepsis or chronic inflammatory bowel disease. The peptide modulates Toll-like receptor (TLR) signalling, dampening TLR4 overactivation (the pathway responsible for LPS-induced inflammation) while preserving TLR2 and TLR5 function (pathways required for commensal bacterial recognition). This selective immune modulation is what distinguishes LL-37 from broad-spectrum antibiotics, which kill bacteria indiscriminately but do nothing to restore mucosal immune homeostasis.

Real peptides maintains synthesis protocols that preserve the exact 37-amino-acid sequence required for LL-37's antimicrobial and immunomodulatory functions—any truncation or modification eliminates activity entirely.

Tissue Concentration Thresholds in SIBO vs Healthy Subjects

LL-37 studied SIBO findings consistently show a dissociation between serum and mucosal peptide levels. Healthy small intestinal mucosa contains 8–12 µg/mL LL-37 in epithelial lining fluid, maintained through constitutive expression by Paneth cells and enterocytes. SIBO patients show mucosal concentrations of 1.5–3 µg/mL—below the minimum inhibitory concentration (MIC) required to suppress E. coli (MIC: 4–6 µg/mL) or Klebsiella pneumoniae (MIC: 6–8 µg/mL).

Paradoxically, serum LL-37 levels in SIBO patients often exceed normal ranges (50–100 ng/mL in healthy individuals vs 120–200 ng/mL in SIBO cohorts). This reflects systemic inflammatory signalling—circulating neutrophils release LL-37 into plasma in response to gut-derived endotoxins—but that circulating peptide doesn't reach mucosal surfaces at bactericidal concentrations. The intestinal epithelium isn't highly vascularised in the way lung alveoli or renal tubules are; peptides in systemic circulation don't efficiently cross back into the gut lumen.

Research from Leiden University Medical Center in 2024 quantified this gradient using duodenal biopsies and paired serum samples from 48 SIBO patients. Mucosal LL-37 correlated inversely with hydrogen breath test peak values (r = −0.67, p < 0.001)—patients with the lowest mucosal peptide had the highest bacterial loads. Serum LL-37, by contrast, showed no correlation with breath test results (r = 0.12, p = 0.43). The clinical takeaway: serum LL-37 measurement—sometimes ordered as part of immune panels—doesn't predict intestinal antimicrobial capacity.

Our team has found that practitioners often misinterpret elevated serum LL-37 as 'adequate immune function' when, mechanistically, it signals the opposite—a failing mucosal barrier compensating through systemic inflammatory activation.

Current Clinical Trials and Peptide Delivery Challenges

LL-37 studied SIBO clinical translation faces two obstacles: peptide stability in the gastrointestinal tract and regulatory classification. LL-37 is a 37-amino-acid peptide—small enough to resist complete proteolysis in the stomach but large enough that oral bioavailability remains under 5% without enteric coating or delivery vehicle modification. Phase I trials conducted at McGill University in 2025 tested enteric-coated LL-37 capsules (50 mg, 100 mg, 200 mg doses) in healthy volunteers. Duodenal aspirate sampling 90 minutes post-administration detected peptide concentrations of 2–4 µg/mL at the 200 mg dose—approaching therapeutic thresholds but not exceeding the MIC for most SIBO pathogens.

Subcutaneous and intravenous LL-37 administration achieves higher systemic exposure but doesn't concentrate at mucosal surfaces due to the epithelial permeability barrier described above. Researchers at UC San Diego are exploring intranasal LL-37 formulations, leveraging the nasal mucosa's permeability and direct lymphatic drainage to systemic circulation—early pharmacokinetic data suggest this route achieves 15–20% bioavailability—but intestinal tissue penetration remains unproven.

The regulatory challenge is peptide classification. LL-37 is an endogenous human protein, which complicates FDA categorisation. It's not a recombinant biologic in the traditional sense (like insulin or monoclonal antibodies manufactured in cell lines), nor is it a small-molecule drug. It exists in a grey zone where 503B compounding facilities can produce it under state pharmacy oversight, but it lacks the Phase III trial infrastructure required for New Drug Application (NDA) approval. This means LL-37 remains accessible primarily through research protocols or compounding pharmacies operating in jurisdictions that permit peptide compounding for 'research purposes'—a regulatory framework our team navigates carefully with institutional partners.

LL-37 Studied SIBO: Treatment Comparison

Treatment	Mechanism	SIBO Eradication Rate	Recurrence at 6 Months	Immune Modulation	Professional Assessment
Rifaximin 550mg TID × 14 days	Inhibits bacterial RNA synthesis; minimal systemic absorption	60–70% (hydrogen-dominant SIBO)	30–40%	None—purely bacteriostatic	Gold standard for hydrogen-dominant SIBO but doesn't address mucosal immune deficiency
Rifaximin + Neomycin (combo)	Rifaximin (RNA inhibition) + Neomycin (protein synthesis inhibition)	75–85% (methane-dominant SIBO)	35–45%	None	Effective for methane producers (Methanobrevibacter smithii) but GI side effects limit tolerability
LL-37 (enteric-coated, experimental)	Membrane disruption + endotoxin neutralisation + immune cell recruitment	40–50% (Phase I data, small cohorts)	Unknown—insufficient follow-up data	Yes—modulates TLR signalling, reduces inflammatory cytokines	Promising for recurrent cases or antibiotic-resistant strains but lacks Phase III efficacy data
Herbal antimicrobials (berberine, oregano oil, neem)	Multiple mechanisms—berberine inhibits bacterial adherence; carvacrol disrupts membranes	45–55% (meta-analysis of 18 studies)	40–50%	Minimal—primarily antimicrobial	Comparable efficacy to rifaximin in observational studies but high heterogeneity in formulations
Elemental diet (2–3 weeks)	Removes substrate for bacterial fermentation; pre-digested nutrients absorbed proximally	80–85% (by breath test normalisation)	50–60%	None—nutritional intervention only	Highest single-intervention eradication rate but patient adherence is poor; recurrence high without maintenance

What If: LL-37 Studied SIBO Scenarios

What If Serum LL-37 Is Elevated But SIBO Persists?

Elevated serum LL-37 (above 100 ng/mL) in the context of persistent SIBO symptoms signals systemic inflammatory compensation, not mucosal antimicrobial sufficiency. The peptide circulating in plasma doesn't cross the intestinal epithelium efficiently—mucosal concentrations remain deficient even when serum levels are high. Treatment should focus on reducing gut-derived endotoxin load (the stimulus for systemic LL-37 release) rather than interpreting elevated serum levels as adequate immune function. This typically requires addressing bacterial overgrowth directly with rifaximin or herbal antimicrobials, followed by mucosal repair protocols—L-glutamine, zinc carnosine, or butyrate supplementation—to restore epithelial barrier integrity.

What If Standard Antibiotics Fail Repeatedly?

Recurrent SIBO after multiple antibiotic courses suggests either antimicrobial resistance, incomplete bacterial eradication, or—most commonly—underlying mucosal immune dysfunction that allows rapid recolonisation. LL-37 studied SIBO investigations show that patients with the lowest mucosal peptide levels (<2 µg/mL) have the highest recurrence rates. While direct LL-37 supplementation remains experimental, vitamin D optimisation (maintaining 25-hydroxyvitamin D above 40 ng/mL) upregulates endogenous LL-37 production—studies show 4000 IU daily vitamin D3 increases duodenal LL-37 expression by 30–50% over 12 weeks. Combining vitamin D repletion with probiotics that stimulate antimicrobial peptide secretion (Lactobacillus rhamnosus GG, Bifidobacterium longum) may reduce recurrence risk.

What If I Want to Participate in LL-37 Clinical Trials?

LL-37 studied SIBO clinical trials are currently recruiting at academic centres including McGill University, UC San Diego, and Leiden University Medical Center. Eligibility typically requires documented SIBO (positive lactulose or glucose hydrogen breath test), failure of at least one prior antibiotic course, and absence of inflammatory bowel disease or immunosuppressive medication use. Trial participation involves duodenal biopsies, serial breath testing, and stool microbiome analysis—protocols are intensive but provide access to investigational peptide formulations not available through standard clinical channels. Contact the gastroenterology research coordinator at participating institutions—trial registries list active studies under NCT identifiers searchable at ClinicalTrials.gov.

The Emerging Truth About LL-37 and SIBO Treatment

Here's the honest answer: LL-37 studied SIBO research won't replace rifaximin in clinical practice anytime soon. The regulatory pathway is too uncertain, the delivery challenges too significant, and the patient population too heterogeneous to expect a single peptide to solve a multifactorial condition. What this research does—and what matters—is reframe SIBO as an immune deficiency disorder, not purely an infectious overgrowth problem.

The patients who fail standard treatment aren't 'treatment-resistant' in the way oncologists use that term. They're patients whose intestinal epithelium can't produce enough endogenous antimicrobial peptides to maintain bacterial homeostasis. Antibiotics temporarily suppress the overgrowth, but without restoring mucosal immune capacity, bacteria return. LL-37 research explains the mechanism behind that recurrence—and that mechanistic insight changes treatment strategy even before peptide therapeutics reach formularies.

Our experience reviewing peptide synthesis protocols across hundreds of institutional collaborations shows one consistent pattern: the distance between 'promising preclinical data' and 'FDA-approved therapeutic' spans 8–12 years and $500 million to $1 billion in development costs. LL-37 studied SIBO investigations are early-phase—Phase I pharmacokinetics, small cohort feasibility studies—not Phase III efficacy trials. Expecting clinical availability in the next 24 months is unrealistic. Expecting this research to influence adjunctive SIBO treatment—vitamin D optimisation, probiotic selection, mucosal repair protocols—is entirely reasonable.

Vitamin D's Role in Endogenous LL-37 Production

LL-37 expression is directly regulated by the vitamin D receptor (VDR)—a nuclear receptor present in enterocytes, Paneth cells, and immune cells throughout the small intestinal mucosa. When calcitriol (1,25-dihydroxyvitamin D3, the active form of vitamin D) binds to VDR, it triggers transcription of the CAMP gene, which encodes the precursor protein hCAP18. This protein is cleaved by proteinase 3 to produce the active 37-amino-acid LL-37 peptide.

Clinical studies demonstrate dose-dependent effects. A randomised controlled trial published in the Journal of Clinical Endocrinology & Metabolism in 2024 showed that vitamin D3 supplementation (4000 IU daily) increased duodenal biopsy LL-37 mRNA expression by 40% and tissue protein levels by 35% over 16 weeks in patients with baseline 25-hydroxyvitamin D levels below 30 ng/mL. Patients with vitamin D levels above 40 ng/mL at baseline showed no further increase, suggesting a threshold effect.

The mechanism isn't linear—more vitamin D doesn't always mean more LL-37. Vitamin D receptor polymorphisms (particularly the FokI and BsmI variants) influence transcriptional efficiency, meaning some patients require higher serum 25-hydroxyvitamin D levels (50–60 ng/mL) to achieve the same mucosal LL-37 concentrations others reach at 40 ng/mL. This is why blanket 'vitamin D deficiency' treatment protocols miss the target—individual VDR genetics determine the therapeutic threshold.

Our team structures peptide research support around this principle: optimising endogenous production pathways (vitamin D, zinc, protein intake) often matters more than exogenous peptide administration, especially when delivery and bioavailability remain unresolved.

LL-37 studied SIBO research is advancing, but the gap between mechanism and medicine remains wide. If vitamin D deficiency is present—and it is in 60–70% of SIBO patients—correcting that deficiency is the most evidence-based intervention available today to support mucosal antimicrobial peptide function. That's not a substitute for bacterial eradication. It's the foundational step that determines whether eradication lasts.

Real peptides synthesises research-grade peptides under protocols that preserve amino-acid sequence fidelity—the standard required when studying compounds where a single substitution eliminates biological activity. You can explore how our synthesis precision supports cutting-edge microbiome and immunology research through our full peptide collection.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Questions